Javascript must be enabled to continue!
Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review
View through CrossRef
Background and Aims:
Identifying individuals with compensated advanced chronic liver disease (cACLD) at risk of decompensation allows for personalized therapy. However, predicting decompensation is challenging, and multiple models have been developed. This study systematically appraises the performance and clinical applications of published multivariable models predicting first decompensation in patients with cACLD or compensated cirrhosis.
Approach and Results:
We searched MEDLINE for liver decompensation prediction models from inception to December 2023. The research was registered with PROSPERO (CRD42023488395). Model risk of bias and applicability were assessed using the Prediction study Risk of Bias Assessment Tool (PROBAST), with results summarized via narrative synthesis. Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies guidelines. Sixteen studies (retrospective and prospective) were included. Seven focused on a single etiology. No study specifically predicted outcomes in persons with alcohol-associated liver disease. Outcome definitions varied, with some models predicting HCC together with decompensation. In total, 27 predictors were included in the models. The most frequent predictors were albumin, platelets, age, liver stiffness, bilirubin, international normalized ratio, and the presence of portal hypertension–related findings during upper gastrointestinal endoscopy. All studies reported discrimination measures, but only 10/16 evaluated calibration. External validation was conducted in 9/16 studies. Thirteen studies were rated as having a high overall risk of bias.
Conclusions:
For clinical utility, a predictive model must accurately describe future risks. Models for predicting decompensation in cACLD are often poorly described, infrequently include patients with ArLD, and lack external validation. These factors are barriers to the clinical utility and uptake of predictive models for first decompensation in patients with cACLD.
Ovid Technologies (Wolters Kluwer Health)
Title: Prediction models for liver decompensation in compensated advanced chronic liver disease: A systematic review
Description:
Background and Aims:
Identifying individuals with compensated advanced chronic liver disease (cACLD) at risk of decompensation allows for personalized therapy.
However, predicting decompensation is challenging, and multiple models have been developed.
This study systematically appraises the performance and clinical applications of published multivariable models predicting first decompensation in patients with cACLD or compensated cirrhosis.
Approach and Results:
We searched MEDLINE for liver decompensation prediction models from inception to December 2023.
The research was registered with PROSPERO (CRD42023488395).
Model risk of bias and applicability were assessed using the Prediction study Risk of Bias Assessment Tool (PROBAST), with results summarized via narrative synthesis.
Reporting followed Preferred Reporting Items for Systematic Reviews and Meta-Analysis and Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies guidelines.
Sixteen studies (retrospective and prospective) were included.
Seven focused on a single etiology.
No study specifically predicted outcomes in persons with alcohol-associated liver disease.
Outcome definitions varied, with some models predicting HCC together with decompensation.
In total, 27 predictors were included in the models.
The most frequent predictors were albumin, platelets, age, liver stiffness, bilirubin, international normalized ratio, and the presence of portal hypertension–related findings during upper gastrointestinal endoscopy.
All studies reported discrimination measures, but only 10/16 evaluated calibration.
External validation was conducted in 9/16 studies.
Thirteen studies were rated as having a high overall risk of bias.
Conclusions:
For clinical utility, a predictive model must accurately describe future risks.
Models for predicting decompensation in cACLD are often poorly described, infrequently include patients with ArLD, and lack external validation.
These factors are barriers to the clinical utility and uptake of predictive models for first decompensation in patients with cACLD.
Related Results
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED] Bridport Health Reviews - Powerfully Detoxifies The Liver, Lose Liver Fat And Improve Gut Health! v1
[RETRACTED]Product Name - Bridport Health Ingredients - Milk Thistle, Beetroot, Artichoke Extract & More. Category - Liver Support Supplement Main Benefits - Helps Protect The ...
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED] Bridport Health Liver Support Does It Really Work v1
[RETRACTED]Depiction • Where to Get Bottle Online –Click Here • Item Name -Bridport Health Liver • Aftereffects - No Major Side Effects • Classification - Health • Accessibility -O...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical activi...
The Portal Hypertension Decompensation Score: A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension
The Portal Hypertension Decompensation Score: A Validated Predictive Model of Liver Decompensation Related to Portal Hypertension
INTRODUCTION:
There is a need for noninvasive risk stratification in people with compensated advanced chronic liver disease (cACLD) to prognosticate and guide managemen...
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Risk factors and severity of acute liver injury in non-chronic liver disease and chronic liver disease patients
Risk factors and severity of acute liver injury in non-chronic liver disease and chronic liver disease patients
Objectives To study factors related to acute liver injury and compare the severity and risk of those factors in patients with and without chronic liver disease. Methods This cross...
Decompensation in Critical Care: Early Prediction of Acute Heart Failure Onset (Preprint)
Decompensation in Critical Care: Early Prediction of Acute Heart Failure Onset (Preprint)
BACKGROUND
Heart failure is a leading cause of mortality and morbidity worldwide. Acute heart failure, broadly defined as rapid onset of new or worsening si...

